Erythromelalgia: Incidence and clinical experience in a single centre in Sweden;Erythromelalgie: Inzidenz und klinische erfahrung in einem Zentrum in Schweden

Vasa - Journal of Vascular Diseases

Volumn 41, Issue 1, 2012, Pages 43-48

  Alhadad, Alaa ^a   Wollmer, Per ^a   Svensson, Åke ^a   Eriksson, Karl Fredrik ^a  

^a Vascular Center   (Sweden)

Author keywords

Eythromelalgia; Incidence; Population based study

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; GUANETHIDINE; ILOPROST;

ADULT; AGED; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; ERYTHEMA; ERYTHROMELALGIA; FEMALE; HIGH TEMPERATURE; HUMAN; INCIDENCE; MALE; MEDICAL RECORD; PAIN; PATIENT IDENTIFICATION; POPULATION BASED CASE CONTROL STUDY; PROGNOSIS; RETROSPECTIVE STUDY; SWEDEN; TISSUE DOPPLER IMAGING; AGE DISTRIBUTION; COMORBIDITY; MIDDLE AGED; PREDICTIVE VALUE; SEX RATIO; TIME;

ADULT; AGE DISTRIBUTION; AGED; COMORBIDITY; ERYTHROMELALGIA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; SWEDEN; TIME FACTORS;

EID: 84858606155     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000162     Document Type: Article

References (25)

1. Babb RR, Alarcon-Segovia D, Fairbairn JF II. Erythermalgia: review of 51 cases. Circulation 1964; 29: 136-41.
2. Bang YJ, Yeo JS, Kim SO, Park YH. Sympathetic block for treating primary erythromelalgia. Korean J Pain 2010; 23: 55-9.
3. Black JA, Dib-Hajj S, McNabola K, Jeste S, Rizzo MA, Kocsis JD etal. Spinal sensory neurons express multiple sodium channel alpha subunit mRNAs. Mol Brain Res 1996, 43: 117-31.
4. Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol 2000; 43: 841-7.
5. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K etal. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006; 444: 894-8.
6. Davis MD, O'Fallon WM, Rogers RS, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol 2000, 136: 330-6.
7. Dib-Hajj SD, Yang Y, Waxman SG. Genetics and molecular patho- physiology of Na(v)1.7-related pain syndromes. Adv Genet 2008; 63: 85-110.
8. Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest 2007; 117: 3603-9.
9. George R, Fulchiero GJ Jr, Marks JG Jr, Clarke JT. Neurovascular in- stability syndrome: a unifying term to describe the coexistence of tem- perature-related vascular disorders in affected patients. Arch Dermatol 2007; 143: 274-5.
10. Kalgaard OM, Mørk C, Kvernebo K. Prostacyclin reduces symptoms and sympathetic dysfunction in erythromelalgia in a double-blind randomized pilot study. Acta Dermatol Venereol 2003; 83: 442-4.
11. Kvernebo K. Erythromelalgia - a condition caused by microvascular arteriovenous shunting. Vasa 1998, 51(Suppl): 1-39.
12. Littleford RC, Khan F, Belch JJ. Impaired skin vasomotor reflexes in patients with erythromelalgia. Clin Sci 1999; 96: 507-12.
13. McCarthy L, Eichelberger L, Skip-worth E, Danielson C. Eryth-romelalgia due to essential throm-bocythemia. Transfusion 2002; 42: 1245.
14. Mitchell SW. On a rare vasomotor neurosis of the extremities and on the maladies with which it may be confounded. Am J Med Sci 1878, 76: 17-36.
15. Mørk C. Erythromelalgia: studies on pathogenesis and therapy [thesis]. University of Oslo, Oslo (Norway), 2004.
16. Mørk C, Kalgaard OM, Kvernebo K. Erythromelalgia as a paraneo-plastic syndrome in a patient with abdominal cancer. Acta Derm Venereol 1999; 79(5): 394.
17. Mørk C, Kvernebo K, Asker CL, Sale-rud EG. Reduced skin capillary den-sity during attacks of erythromelal-gia implies arteriovenous shunting as pathogenetic mechanism. J Invest Dermatol 2002; 119: 949-53.
18. Mørk C, Salerud EG, Asker CL, Kvernebo K. The prostaglandin E1 analog misoprostol reduces symptoms and microvascular arterio-venous shunting in erythromelal-gia-a double-blind, crossover,placebo-compared study. J Invest Dermatol 2004; 122: 587-93.
19. Nathan A, Rose JB, Guite JW, Hehir D, Milovcich K. Primary eryth-romelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. Pediatrics 2005, 115: e504-e7.
20. Orstavik K, Mørk C, Kvernebo K, Jørum E. Pain in primary eryth- romelalgia-a neuropathic component? Pain 2004; 110: 531-8
21. Orstavik K, Weidner C, Schmidt R, Schmelz M, Hilliges M, Jorum E et al. Pathological C-fibres in patients with a chronic painful condition. Brain 2003; 126: 567-78.
22. Reed KB, Davis MD. Incidence of erythromelalgia: a population-based study in Olmsted County, Minnesota. J Eur Acad Dermatol Venereol 2009; 23: 13-5.
23. Siv B. Laser Doppler Flowmetry and Imaging: Methodological Studies. [thesis]. Malmö University Hospital, Malmö, (Sweden), 1998.
24. Toledo-Aral JJ, Moss BL, He ZJ, Koszowski AG, Whisenand T, Levin-son SR et al. Identification of PN1, a predominant voltage-dependent so-dium channel expressed principally in peripheral neurons. Proc Natl Acad Sci USA 1997, 94: 1527-32.
25. Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004, 1: 171-4.